-
公开(公告)号：US07973078B2
公开(公告)日：2011-07-05
申请号：US12297445
申请日：2007-08-09
申请人： Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
发明人： Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
IPC分类号： C07C303/00 , A01N41/06
CPC分类号： C07C311/29 , A61K31/18 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/235 , A61K31/24 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/404 , A61K31/415 , A61K31/4196 , A61K31/423 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , C07C311/14 , C07C311/19 , C07C311/21 , C07C311/47 , C07C311/51 , C07C323/49 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D207/27 , C07D207/325 , C07D209/08 , C07D213/40 , C07D213/68 , C07D213/70 , C07D213/79 , C07D213/89 , C07D215/12 , C07D217/06 , C07D231/12 , C07D237/08 , C07D239/26 , C07D241/12 , C07D249/08 , C07D263/32 , C07D263/58 , C07D277/20 , C07D277/28 , C07D277/36 , C07D295/12 , C07D307/52 , C07D307/81 , C07D333/20 , C07D333/34 , C07D333/38 , C07D333/40 , C07D333/58
摘要： A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
摘要翻译： 可用作治疗与EP1受体相关疾病，特别是下尿路症状的药物的化合物。 证实具有酰胺结构的磺酰胺化合物，其特征在于其中酰胺中的碳原子与磺酰胺中的N原子通过低级亚烷基或其盐键合的化学结构具有有效的EP1受体拮抗活性，完成 本发明。 由于本发明的磺酰胺化合物或其药学上可接受的盐具有有效的EP1受体拮抗活性，因此可用作治疗与EP1受体，特别是下尿路症状相关的疾病的药剂。
-
公开(公告)号：US20050130224A1
公开(公告)日：2005-06-16
申请号：US10516133
申请日：2003-06-02
申请人： Seiji Saito , Kazuki Ono , Mitsuhito Wada , Kensaku Imai , Shinya Hosogi , Takashi Shimada
发明人： Seiji Saito , Kazuki Ono , Mitsuhito Wada , Kensaku Imai , Shinya Hosogi , Takashi Shimada
摘要： Objective sequence data (10) which is primary sequence information on an objective protein is entered in an interaction site predicting device by the user. A secondary structure prediction simulation is executed on the objective sequence data (10) entered for secondary structure prediction programs (20a to 20d) that predict a secondary structure of a protein from primary sequence information of the protein. Results of secondary structure prediction (30a to 30d) from the respective secondary structure prediction programs (20a to 20d) are compared (60). Based on the comparison result, frustration of a local portion in the primary sequence information of the objective protein is calculated (70). An interaction site of the objective protein is predicted from the calculated frustration of the local portion (80).
摘要翻译： 作为目标蛋白质的主序列信息的目标序列数据（10）由用户输入到交互站点预测装置。 对从二级结构预测程序（20a到20d）输入的目标序列数据（10）执行二级结构预测模拟，其从蛋白质的一级序列信息预测蛋白质的二级结构。 比较来自各个二级结构预测程序（20a至20d）的二级结构预测（30a至30d）的结果（60）。 基于比较结果，计算目标蛋白的一级序列信息中局部部分的挫败（70）。 目标蛋白质的相互作用位点是从计算出的局部部分的挫折中预测的（80）。
-
公开(公告)号：US20090312328A1
公开(公告)日：2009-12-17
申请号：US12297445
申请日：2007-08-09
申请人： Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
发明人： Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
IPC分类号： A61K31/18 , C07C311/21 , C07D213/56 , C07D239/26 , C07D295/155 , C07D241/08 , A61K31/222 , A61K31/195 , A61K31/44 , A61K31/4406 , A61K31/505 , A61K31/4965 , A61K31/5375 , A61P13/00
CPC分类号： C07C311/29 , A61K31/18 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/235 , A61K31/24 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/404 , A61K31/415 , A61K31/4196 , A61K31/423 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , C07C311/14 , C07C311/19 , C07C311/21 , C07C311/47 , C07C311/51 , C07C323/49 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D207/27 , C07D207/325 , C07D209/08 , C07D213/40 , C07D213/68 , C07D213/70 , C07D213/79 , C07D213/89 , C07D215/12 , C07D217/06 , C07D231/12 , C07D237/08 , C07D239/26 , C07D241/12 , C07D249/08 , C07D263/32 , C07D263/58 , C07D277/20 , C07D277/28 , C07D277/36 , C07D295/12 , C07D307/52 , C07D307/81 , C07D333/20 , C07D333/34 , C07D333/38 , C07D333/40 , C07D333/58
摘要： [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.[Means for Solution] It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
摘要翻译： [对象]可用作治疗与EP1受体，特别是下尿路症状相关的疾病的药剂的化合物。 [溶液的方法]确认具有酰胺结构的磺酰胺化合物，其特征在于其中酰胺中的氨基与磺酰胺中的N原子通过低级亚烷基或其盐键合的化学结构具有有效的EP1 受体拮抗活性，完成本发明。 由于本发明的磺酰胺化合物或其药学上可接受的盐具有有效的EP1受体拮抗活性，因此可用作治疗与EP1受体，特别是下尿路症状相关的疾病的药剂。
-
-
搜索结果
3 条记录 (耗时 0.014 秒)
